SlideShare a Scribd company logo
1
Automobiles (3 wheelers)
Atul Auto
Sensex: 28420 CMP: INR 480
Expandingcapacityby1.5x
Atul Auto has current capacity of 48000 units. The company plans
to expand capacity by 1.5x to 120000 units in the next 2 years.
While capacity of 12000 units will be created by removing some
bottlenecks at the existing unit at an investment of INR 30-50 mn,
another 60000 units expansion will take place at a greenfield
plant in Ahmedabad. Total investment for the new plant would be
~INR 1.50 bn of which INR 0.40 bn has already been invested. The
company plans to undertake the commercial production of the
new plant in or before FY18. Atul's current capacity is miniscule
compared to the established players in the industry and their
capacity enhancement plans will help them in achieving scale.
Product Portfolio
Currently Atul Auto's product portfolio comprises of 45 variants
under 4 brands i.e. Shakti, Smart, Gem and Gemini. The company
plans to launch its new 0.35 ton petrol 3 wheeler in H2FY16. Petrol
3 wheelers account for 46% of passenger 3 wheeler market in
India and almost 100% of passenger 3 wheeler exports from India.
The company enjoys a market share of ~7.5% in India despite
being present in only ~56% of the market. With the launch of this
new vehicle, we expect Atul Auto to further expand its market
share in India.
Aggressive Export plans
Exports account for 43% of total Indian 3 wheeler industry sales
whereas it accounts for 3.5% of Atul Auto's sales. Almost entire
July 21, 2015 VISITNOTE
export market of 408000 units of 3 wheelers is 0.35 ton petrol.
While previously Atul was not present in the segment, now with
its 0.35 ton 3 wheeler, we expect the company to clock significant
growth in export volumes with its widening target audience. The
company too plans to scale up export volumes to more than 10000
units over the next 3-5 years.
Industry Outlook
The management expects 3 wheeler industry to grow at a CAGR of
6%-8% in the medium term. Both passenger and goods 3 wheelers
are expected to grow on the back of demand from both urban and
rural areas. Atul Auto also expects limited competition & impact
from electric 3 wheelers (or E-rickshaws) and RE60 of Bajaj Auto
as these vehicles are likely to find buyers only in urban areas and
feeder routes. The company anyways till now does not have
significant presence in urban markets.
Outlook & Valuation
Atul Auto, being a relatively small player in the 3 wheeler
industry, is expected to grow on the back of widening product
portfolio, growing distribution reach and expanding market
opportunity size. Increase in capacity by 1.5x will help the
company in achieving scale, enhance market share and fulfill
the near term vision of the management of achieving sales of
100000 3-wheelers. Topline and bottomline grew at a CAGR of
16.4% and 23.4% between FY13-15. At CMP the stock is trading
at a PE of 25.8x FY15 earnings.
Shareholding (%) Mar-15
Promoters 52.70
FIIs 11.45
DIIs 8.27
Others 27.58
Relative Price Performance
Key Data
BSE Code 531795
NSE Code ATULAUTO
Bloomberg Code ATA IN
Reuters Code ATUL.BO
Shares Outstanding (mn) 21.94
Face Value 5
Mcap (INR bn) 10.25
52 Week H/L 722.00/264.13
2W Avg. Qty.NSE 72189
Free Float (INR Bn) 4.85
Beta 1.24
(INR mn) FY12 FY13 FY14 FY15
Net Sales 2988 3638 4301 4928
Growth (%) 47.90% 21.76% 18.22% 14.57%
EBIDTAM (%) 8.86% 11.01% 10.55% 11.75%
Adj. PAT 155 259 296 394
Growth (%) 64.28% 66.89% 14.45% 33.13%
Adj. EPS (INR) 20.54 23.11 26.45 17.61
P/E(x) 5.41 6.27 13.32 30.91
EV/EBIDTA 2.89 3.10 7.70 20.58
Net Debt/Equity 0.07 0.00 0.00 0.00
RoACE (%) 28.02% 36.96% 33.21% 33.25%
RoAE (%) 32.17% 39.71% 35.11% 36.60%
We met the management of Atul Auto and visited their manufacturing facilities to understand the dynamics of the
3 wheeler industry & steps they are taking to further strengthen their market share. The company plans to launch 0.35 ton petrol
3 wheeler this year which will complete its product portfolio and expand its addressable market size. Atul Auto's medium term
strategy is to achieve 100000 unit sales and INR 1000 crs turnover. Given below are the key takeaways from the visit:-
Prashant Biyani
prashant.biyani@spagroupindia.com
Ph. No. 91 33 4011 4800 (Ext. 833)
40
60
80
100
120
140
160
Jul-14
Aug-14
Sep-14
Oct-14
Nov-14
Dec-14
Jan-15
Feb-15
Mar-15
Apr-15
May-15
Jun-15
Jul-15
Atul Auto Sensex
2
Automobiles (3 wheelers)
Financials
Income Statement
Year End March (INR mn) FY12 FY13 FY14 FY15
Net Sales 2988 3638 4301 4928
Growth in Sales (%) 47.90% 21.76% 18.22% 14.57%
Cost of goods sold 2376 2843 3317 3722
Employees Cost 156 197 257 324
Other Expenses 174 181 247 303
Total Expenditure 2724 3238 3847 4349
EBIDTA (without OI) 265 401 454 579
% Growth -36.23% -51.38% -13.28% -27.58%
EBITDA Margin % 8.86% 11.01% 10.55% 11.75%
Depreciation/Amortization 43 44 52 56
EBIT 222 356 402 523
EBIT Margin % 7.43% 9.79% 9.34% 10.62%
Interest Expense 8 4 4 6
Other Income 18 20 30 75
Exceptionals 1 0 2 11
EBT 232 372 428 593
Tax Expenses 77 113 130 187
APAT 155 259 296 394
% Growth 64.28% 66.89% 14.45% 33.13%
APAT Margin % 5.19% 7.11% 6.89% 8.00%
Balance Sheet
Year End March (INR mn) FY12 FY13 FY14 FY15
Sources of funds
Share capital 76 112 112 112
Reserves & Surplus 485 631 833 1099
Total Networth 561 743 945 1211
Total Debt 39 0 0 0
Total Liabilities 600 743 945 1211
Application of funds
Net Block 400 431 527 799
Capital Work-in-Progress 16 50 6 0
Investments 12 12 12 10
Total Current Assets 493 699 851 892
Total Current Liabilities 299 440 438 507
Net Current Assets 194 258 413 385
Net Deferred Tax (47) (45) (61) (52)
Other Assets 25 37 47 68
Total Assets 600 743 945 1211
Cash Flow
Year End March (INR mn) FY12 FY13 FY14 FY15
EBT 232 372 428 593
Less: Other Income/Exceptionals (18) (20) (30) (75)
Add:Depreciation 43 44 52 56
Add: Interest paid 8 4 4 6
Direct taxes paid (70) (122) (134) 0
Change in Working Capital (26) 202 (84) (150)
Cash Flow from operations (a) 169 481 236 429
Change in Fixed Assets 20 (75) (148) (327)
Change in CWIP (16) (34) 44 6
Change in Investments 11 0 0 12
Others (38) (12) (11) (21)
Cash Flow from Investing (b) (23) (121) (115) (329)
Change in Equity 15 37 0 0
Debt Raised/(Repaid) (21) (39) 0 0
Dividend paid (27) (43) (77) (96)
Interest paid (8) (4) (4) (6)
Others (20) (44) 30 (176)
Cash Flow from Financing (c ) (61) (93) (50) (278)
Net Change in Cash (a+b+c) 85 267 71 (178)
Opening Cash 28 114 381 452
Closing Cash 114 381 451 274
Key Ratios
Year End March FY12 FY13 FY14 FY15
Per Share Data (INR)
Adj. EPS 20.54 23.11 26.45 17.61
Growth (%) 32.29% 12.50% 14.45% -33.44%
CEPS 35.43 54.35 62.43 80.68
DPS 4.85 5.88 7.35 5.00
BVPS 74.29 66.34 84.34 54.05
Return Ratios (%)
RoACE 28.02% 36.96% 33.21% 33.25%
RoANW 32.17% 39.71% 35.11% 36.60%
Liquidity Ratios
Net Debt/Equity 0.07 0.00 0.00 0.00
Current Ratio 1.65 1.59 1.94 1.76
Efficiency Ratios
Asset Turnover Ratio 5.62 5.42 5.10 4.57
Inventory Days 38 34 25 24
Debtor Days 7 7 9 17
Creditor days 18 24 28 28
Valuation Ratios
P/E(x) 5.41 6.27 13.32 30.91
P/BV (x) 1.50 2.19 4.18 10.07
P/CEPS (x) 3.14 2.67 5.64 6.74
Dividend Yield (%) 4.36% 4.05% 2.09% 0.92%
EV/Net Sales (x) 0.26 0.34 0.81 2.42
EV/EBIDTA(x) 2.89 3.10 7.70 20.58
3
Automobiles (3 wheelers)
For More Information Visit Us At : www.spasecurities.com
Sharad Avasthi Head - Equity Research sharad.avasthi@spagroupindia.com Tel.: +91-33-4011 4800 Ext.832
SPA Securities Ltd: Mittal Court, A-Wing, 10th Floor, Nariman Point, Mumbai - 400 021, Tel. No. : +91-022-4289 5600, Fax: +91 (22) 2657 3708/9
Analyst Certification of Independence: The analyst(s) for this report certifies that all the views expressed in this report accurately reflect his or her personal views about the subject company(ies) or issuers and no part of his or
hercompensationwas,isorwillbe,directlyorindirectlyrelatedtospecificrecommendationsorviewsexpressedinthisreport.Theresearchanalystsareboundbystringentinternalregulationsandalsolegalandstatutoryrequirements
of the Securities and Exchange Board of India (hereinafter "SEBI") and the analysts' compensation are completely delinked from all the other companies and/or entities of SPASecurities Limited, and have no bearing whatsoever on
anyrecommendationthattheyhavegivenintheResearchReport.
DisclaimerandDisclosuresasrequiredunderSEBI(Research Analyst)Regulations,2014:SPASecuritiesLimited(hereinafterreferasSPASecurities)anditsaffiliatesareengagedininvestmentbanking,investment advisory,
stock broking, institutional equities, Mutual Fund Distributor and insurance broking. SPASecurities is a SEBI registered securities broking Company having membership of NSE, BSE & MCX for Equity, Future & Option, Currency
Derivatives segment and Wholesale Debt Market. The Company is focused primarily on providing securities broking services to institutional clients and is empanelled as an approved securities broker with all the major Nationalised,
PrivateandCo-operativebanks,Corporatehouses,InsuranceCompanies,FinancialInstitutions,AssetManagementCompaniesandProvidentFundTrusts.Detailsofaffiliatesareavailableonourwebsitei.e.www.spasecurities.com.
Weherebydeclarethatouractivitieswereneithersuspendednorwehavedefaultedwithanystockexchangeauthoritywithwhom weareregisteredinthelastfiveyears.WehavenotbeendebarredfromdoingbusinessbyanyStock
Exchange/SEBI or any other authorities, nor has our certificate of registration been cancelled by SEBI at any point of time.
GeneralDisclosures: ThisResearchReport(hereinaftercalled"report")hasbeenpreparedbySPASecuritiesandismeantforsoleusebytherecipientandnotforcirculation.ThisReportdoesnotconstituteapersonalrecommendation
or take into account the particular investment objectives, financial situations, or needs of individual clients. The recommendations, if any, made herein are expression of views and/or opinions and should not be deemed or construed
tobeneitheradviceforthepurposeofpurchaseorsaleofanysecurity,(asdefinedundersection2(h)ofsecuritiesContracts(Regulation)Act.1956,throughSPASecuritiesnoranysolicitationorofferingofanyinvestment/tradingopportunity
onbehalfoftheissuer(s)oftherespectivesecurity(ies)referredtoherein.RecipientsofthisReportshouldrelyoninformation/dataarisingoutoftheirowninvestigations.Readersareadvisedtoseekindependentprofessionaladvice
and arrive at an informed trading/investment decision before executing any trades or making any investments.
ThisReporthasbeenpreparedonthebasisofpubliclyavailableinformation,internallydevelopeddataandothersourcesbelievedbySPASecuritiestobereliable,althoughitsaccuracyandcompletenesscannotbeguaranteed.Such
information has not been independently verified and no guaranty, representation of warranty, express or implied, is made as to its accuracy, completeness or correctness.Any review, retransmission or any other use is prohibited.
The information, opinions, views expressed in this Research Report are those of the research analyst as at the date of this Research Report which are subject to change and do not represent to be an authority on the subject. While
we would endeavour to update the information herein on a reasonable basis, we are under no obligation to update the information.Also, there may be regulatory, compliance or other reasons that prevent us from doing so. Hence all
such information and opinions are subject to change without notice.
Our salespeople, traders, and other professionals may provide oral or written market commentary or trading strategies to our clients that reflect opinions that are contrary to the opinions expressed herein, and our proprietary trading
and investing businesses may make investment decisions that may be inconsistent with the recommendations expressed herein.
This Research Report should be read and relied upon at the sole discretion and risk of the recipient. If you are dissatisfied with the contents of this complimentary Research Report or with the terms of this Disclaimer, your sole and
exclusive remedy is to stop using this Research Report. Neither SPASecurities nor its affiliates or their respective directors, employees, agents or representatives shall be responsible or liable in any manner, directly or indirectly, for
the losses or the damages sustained due to the investments made or any action taken on basis of this report, including but not restricted to, fluctuation in the prices of shares and bonds, changes in the currency rates, diminution in
the NAVs, reduction in the dividend or income, etc.
Compensation of our ResearchAnalysts is not based on any specific merchant banking, investment banking or brokerage service transactions. SPASecurities may have issued other reports in the past that are inconsistent with and
reachdifferentconclusionfromtheinformationpresentedinthisreport.
SPASecurities, its affiliates and employees may, from time to time, effect or have effected an own account transaction in, or deal as principal or agent in or for the securities mentioned in this document.They may perform or seek to
perform investment banking or other services for, or solicit investment banking or other business from, any company referred to in this report.
TheusershouldconsulttheirownadvisorstodeterminethemeritsandrisksofinvestmentandalsoreadtheRiskDisclosureDocumentsforCapitalMarketsandDerivativeSegmentsasprescribedbySecuritiesandExchangeBoard
of India before investing in the Indian Markets.
A graph of daily closing prices of securities is available at www.nseindia.com and http://economictimes.indiatimes.com/markets/stocks/stock-quotes. (Choose a company from the list on the browser and select the "three years" icon
in the price chart).
SPASecurities plans to register itself as a Research Entity under the SEBI (ResearchAnalysts) Regulations, 2014.
Disclaimers in respect of jurisdiction: This report is not directed to, or intended for distribution to or use by, any person or entity who is a citizen or resident or located in any locality, state, country or other jurisdiction where such
distribution, publication, reproduction, availability or use would be contrary to law or regulation or what would subject SPASecurities or its affiliates to any registration or licensing requirement within such jurisdiction. If this report is
inadvertentlysendorhasreachedanyindividualinsuchcountry,especially,USA,thesamemaybeignoredandbroughttotheattentionofthesender.Thisdocumentmaynotbereproduced,distributedorpublishedforanypurposes
without prior written approval of SPASecurities.
List of Associates as per SEBI (Research Analyst) Regulations, 2014
• SPAInsurance Broking Services limited
Statements on ownership and material conflicts of interest, compensation - SPA and Associates
Disclosure of interest statement Yes/No
SPA Securities/its Affiliates/Analyst/his or her Relative financial interest in the company No
SPA Securities/its Affiliates/Analyst/his or her Relative actual/beneficial ownership of more than 1% in subject company at the end of the month
Immediately preceding the date of the publication of the research report or date of public appearance. No
Investment banking relationship with the company covered No
Any other material conflict of interest at the time of publishing the research report No
Receipt of compensation by SPA Securities or its Affiliated Companies from the subject company covered for in the last twelve months:
• Managing/co-managing public offering of securities
• Investmentbanking/merchantbanking/brokerageservices
• products or services other than those above
• in connection with research report
No
Whether Research Analyst has served as an officer, director or employee of the subject company covered No
Whether the Research Analyst or Research Entity has been engaged in market making activity of the Subject Company; No
For statements on ownership and material conflicts of interest, compensation, etc. for individual Research Analyst(s), please refer to each specific research report.
SPA CAPITAL SERVICES LIMITED
Investment Advisory Services,
AMFI Reg. No. ARN-0007
SPA CAPITAL ADVISORS LIMITED
SEBI registered Category-1
Merchant Bankers
SEBI Regn. No. INM000010825
SPA COMTRADE PRIVATE LIMITED
Member of NCDEX & MCX.
NCDEX TMID-00729,
NCDEXFMCNo.NCDEX/TCM/CORP/0714
SPAINSURANCE BROKING SERVICES LTD
Direct Broker for Life and General
Insurance Broking
IRDA Lic. Code No. DB053/03
SPA Securities Ltd SEBI Reg. Nos.
NSE Cash INB231178238
NSE Future & Option INF231173238
NSE Currency Derivatives INE231178238
BSE Cash INB011178234
BSE Currency Derivatives INE011178234
MCX-SX Cash INB261178231
MCX-SX Future & Option INF261178231
MCX-SX Currency Derivatives INE261178238
Mutual Fund ARN 77388
CDSLDP IN-DP-CDSL-485-2008
NSDLDP IN-DP-NSDL-316-2009

More Related Content

What's hot

Equity Research Report Ways2Capital 27 july 2015
Equity Research Report Ways2Capital 27 july 2015 Equity Research Report Ways2Capital 27 july 2015
Equity Research Report Ways2Capital 27 july 2015
Ways2Capital | Investment Advisor
 
Equity report Ways2Capital 04 may 2015
Equity report Ways2Capital 04 may 2015Equity report Ways2Capital 04 may 2015
Equity report Ways2Capital 04 may 2015
Ways2Capital | Investment Advisor
 
Buy Abbott India; Pharma sector to grow at CAGR of 20% over next 5 years
Buy Abbott India; Pharma sector to grow at CAGR of 20% over next 5 yearsBuy Abbott India; Pharma sector to grow at CAGR of 20% over next 5 years
Buy Abbott India; Pharma sector to grow at CAGR of 20% over next 5 yearsIndiaNotes.com
 
Daily report 20 july
Daily report 20 julyDaily report 20 july
Daily report 20 july
tradenivesh investment
 
Equity bazaar 06.05.2016
Equity bazaar 06.05.2016Equity bazaar 06.05.2016
Equity bazaar 06.05.2016
Choice Equity
 
Eastern Financiers' Daily Market Outlook
Eastern Financiers' Daily Market OutlookEastern Financiers' Daily Market Outlook
Eastern Financiers' Daily Market Outlook
IndiaNotes.com
 
Most trusted equity news
Most trusted equity newsMost trusted equity news
Most trusted equity news
Riya jain
 
Grasim Industries reports improved performance in Q1FY16
Grasim Industries reports improved performance in Q1FY16Grasim Industries reports improved performance in Q1FY16
Grasim Industries reports improved performance in Q1FY16
IndiaNotes.com
 
Apollo Tyres approves further expansion of the Truck & Bus radial tyre capacity
Apollo Tyres approves further expansion of the Truck & Bus radial tyre capacityApollo Tyres approves further expansion of the Truck & Bus radial tyre capacity
Apollo Tyres approves further expansion of the Truck & Bus radial tyre capacity
IndiaNotes.com
 
GSK Consumer: Horlicks strengthens its position as No.1 brand across India
GSK Consumer: Horlicks strengthens its position as No.1 brand across IndiaGSK Consumer: Horlicks strengthens its position as No.1 brand across India
GSK Consumer: Horlicks strengthens its position as No.1 brand across India
IndiaNotes.com
 
Vidhi Dyestuffs: To keep its growth story in the coming quarters also
Vidhi Dyestuffs: To keep its growth story in the coming quarters alsoVidhi Dyestuffs: To keep its growth story in the coming quarters also
Vidhi Dyestuffs: To keep its growth story in the coming quarters also
IndiaNotes.com
 
Welspun Corp's net jumps to Rs163.80 mn in Q1FY16; Maintain buy
Welspun Corp's net jumps to Rs163.80 mn in Q1FY16; Maintain buyWelspun Corp's net jumps to Rs163.80 mn in Q1FY16; Maintain buy
Welspun Corp's net jumps to Rs163.80 mn in Q1FY16; Maintain buy
IndiaNotes.com
 
Equity Research Report 12 May 2015 Ways2Capital
Equity Research Report 12 May 2015 Ways2CapitalEquity Research Report 12 May 2015 Ways2Capital
Equity Research Report 12 May 2015 Ways2Capital
Ways2Capital | Investment Advisor
 
Hester Biosciences gets manufacturing licence for 2 additional poultry vaccines
Hester Biosciences gets manufacturing licence for 2 additional poultry vaccinesHester Biosciences gets manufacturing licence for 2 additional poultry vaccines
Hester Biosciences gets manufacturing licence for 2 additional poultry vaccines
IndiaNotes.com
 
Equity report ways2capital 03 march 2015
Equity report ways2capital 03 march 2015Equity report ways2capital 03 march 2015
Equity report ways2capital 03 march 2015
Ways2Capital | Investment Advisor
 
Equity daily report_ 21 aug 2018
Equity daily report_ 21 aug 2018Equity daily report_ 21 aug 2018
Equity daily report_ 21 aug 2018
tradenivesh investment
 
Trend today report money classic research
Trend today report money classic researchTrend today report money classic research
Trend today report money classic research
Money Classic Research
 
Weekly equity report by capital height
Weekly equity report by capital heightWeekly equity report by capital height
Weekly equity report by capital height
Money CapitalHeight Research Investment Advisers Pvt Ltd
 

What's hot (19)

Equity Research Report Ways2Capital 27 july 2015
Equity Research Report Ways2Capital 27 july 2015 Equity Research Report Ways2Capital 27 july 2015
Equity Research Report Ways2Capital 27 july 2015
 
Equity report Ways2Capital 04 may 2015
Equity report Ways2Capital 04 may 2015Equity report Ways2Capital 04 may 2015
Equity report Ways2Capital 04 may 2015
 
Buy Abbott India; Pharma sector to grow at CAGR of 20% over next 5 years
Buy Abbott India; Pharma sector to grow at CAGR of 20% over next 5 yearsBuy Abbott India; Pharma sector to grow at CAGR of 20% over next 5 years
Buy Abbott India; Pharma sector to grow at CAGR of 20% over next 5 years
 
Daily report 20 july
Daily report 20 julyDaily report 20 july
Daily report 20 july
 
Equity bazaar 06.05.2016
Equity bazaar 06.05.2016Equity bazaar 06.05.2016
Equity bazaar 06.05.2016
 
Eastern Financiers' Daily Market Outlook
Eastern Financiers' Daily Market OutlookEastern Financiers' Daily Market Outlook
Eastern Financiers' Daily Market Outlook
 
Daily equity report
Daily equity reportDaily equity report
Daily equity report
 
Most trusted equity news
Most trusted equity newsMost trusted equity news
Most trusted equity news
 
Grasim Industries reports improved performance in Q1FY16
Grasim Industries reports improved performance in Q1FY16Grasim Industries reports improved performance in Q1FY16
Grasim Industries reports improved performance in Q1FY16
 
Apollo Tyres approves further expansion of the Truck & Bus radial tyre capacity
Apollo Tyres approves further expansion of the Truck & Bus radial tyre capacityApollo Tyres approves further expansion of the Truck & Bus radial tyre capacity
Apollo Tyres approves further expansion of the Truck & Bus radial tyre capacity
 
GSK Consumer: Horlicks strengthens its position as No.1 brand across India
GSK Consumer: Horlicks strengthens its position as No.1 brand across IndiaGSK Consumer: Horlicks strengthens its position as No.1 brand across India
GSK Consumer: Horlicks strengthens its position as No.1 brand across India
 
Vidhi Dyestuffs: To keep its growth story in the coming quarters also
Vidhi Dyestuffs: To keep its growth story in the coming quarters alsoVidhi Dyestuffs: To keep its growth story in the coming quarters also
Vidhi Dyestuffs: To keep its growth story in the coming quarters also
 
Welspun Corp's net jumps to Rs163.80 mn in Q1FY16; Maintain buy
Welspun Corp's net jumps to Rs163.80 mn in Q1FY16; Maintain buyWelspun Corp's net jumps to Rs163.80 mn in Q1FY16; Maintain buy
Welspun Corp's net jumps to Rs163.80 mn in Q1FY16; Maintain buy
 
Equity Research Report 12 May 2015 Ways2Capital
Equity Research Report 12 May 2015 Ways2CapitalEquity Research Report 12 May 2015 Ways2Capital
Equity Research Report 12 May 2015 Ways2Capital
 
Hester Biosciences gets manufacturing licence for 2 additional poultry vaccines
Hester Biosciences gets manufacturing licence for 2 additional poultry vaccinesHester Biosciences gets manufacturing licence for 2 additional poultry vaccines
Hester Biosciences gets manufacturing licence for 2 additional poultry vaccines
 
Equity report ways2capital 03 march 2015
Equity report ways2capital 03 march 2015Equity report ways2capital 03 march 2015
Equity report ways2capital 03 march 2015
 
Equity daily report_ 21 aug 2018
Equity daily report_ 21 aug 2018Equity daily report_ 21 aug 2018
Equity daily report_ 21 aug 2018
 
Trend today report money classic research
Trend today report money classic researchTrend today report money classic research
Trend today report money classic research
 
Weekly equity report by capital height
Weekly equity report by capital heightWeekly equity report by capital height
Weekly equity report by capital height
 

Similar to Atul Auto: Aims at Rs1000 cr turnover in the medium term

Lumax Industries quarterly results above estimates; buy
Lumax Industries quarterly results above estimates; buyLumax Industries quarterly results above estimates; buy
Lumax Industries quarterly results above estimates; buy
IndiaNotes.com
 
Ashok Leyland Q1FY15: Losses narrowed down to Rs48 mn, hold
 Ashok Leyland Q1FY15: Losses narrowed down to Rs48 mn, hold Ashok Leyland Q1FY15: Losses narrowed down to Rs48 mn, hold
Ashok Leyland Q1FY15: Losses narrowed down to Rs48 mn, hold
IndiaNotes.com
 
Mahindra &Mahindra Q1FY15 profits better than estimates - Hold - SPA Securities
Mahindra &Mahindra Q1FY15 profits better than estimates - Hold - SPA SecuritiesMahindra &Mahindra Q1FY15 profits better than estimates - Hold - SPA Securities
Mahindra &Mahindra Q1FY15 profits better than estimates - Hold - SPA Securities
IndiaNotes.com
 
ATS Company Reports: Nrb bearing
ATS Company Reports: Nrb bearingATS Company Reports: Nrb bearing
ATS Company Reports: Nrb bearing
Aditya Trading Solutions Pvt Ltd
 
Gabriel India: Q4FY15 net profit up 55.52% y/y to INR129.55m; 'Buy'
Gabriel India: Q4FY15 net profit up 55.52% y/y to INR129.55m; 'Buy'Gabriel India: Q4FY15 net profit up 55.52% y/y to INR129.55m; 'Buy'
Gabriel India: Q4FY15 net profit up 55.52% y/y to INR129.55m; 'Buy'
IndiaNotes.com
 
Skipper remains leading player in the transmission tower business
Skipper remains leading player in the transmission tower businessSkipper remains leading player in the transmission tower business
Skipper remains leading player in the transmission tower business
IndiaNotes.com
 
Setco Automotive Q1FY15: Revenue in-line; PAT below estimates - SPA Securities
Setco Automotive Q1FY15: Revenue in-line; PAT below estimates - SPA SecuritiesSetco Automotive Q1FY15: Revenue in-line; PAT below estimates - SPA Securities
Setco Automotive Q1FY15: Revenue in-line; PAT below estimates - SPA SecuritiesIndiaNotes.com
 
Cyient announces acquisition of GSE-Asia, maintain hold
Cyient announces acquisition of GSE-Asia, maintain holdCyient announces acquisition of GSE-Asia, maintain hold
Cyient announces acquisition of GSE-Asia, maintain hold
IndiaNotes.com
 
Voltas Q4FY15: Firstcall recommend 'Buy'
Voltas Q4FY15: Firstcall recommend 'Buy'Voltas Q4FY15: Firstcall recommend 'Buy'
Voltas Q4FY15: Firstcall recommend 'Buy'
IndiaNotes.com
 
ATS Company Reports: Elgi equipments ltd.
ATS Company Reports: Elgi equipments ltd.ATS Company Reports: Elgi equipments ltd.
ATS Company Reports: Elgi equipments ltd.
Aditya Trading Solutions Pvt Ltd
 
Patel Integrated Logistics: FY15 net profit up 155%; transportation sector re...
Patel Integrated Logistics: FY15 net profit up 155%; transportation sector re...Patel Integrated Logistics: FY15 net profit up 155%; transportation sector re...
Patel Integrated Logistics: FY15 net profit up 155%; transportation sector re...
IndiaNotes.com
 
ENIL 1QFY18
ENIL 1QFY18ENIL 1QFY18
ENIL 1QFY18
Mohit Jn
 
Medium to Long Term Investment Idea: Capital Trust
Medium to Long Term Investment Idea: Capital TrustMedium to Long Term Investment Idea: Capital Trust
Medium to Long Term Investment Idea: Capital Trust
IndiaNotes.com
 
Castrol India clocks Q1CY15 net profit of INR1,467m; Firstcall recommends 'Buy'
Castrol India clocks Q1CY15 net profit of INR1,467m; Firstcall recommends 'Buy'Castrol India clocks Q1CY15 net profit of INR1,467m; Firstcall recommends 'Buy'
Castrol India clocks Q1CY15 net profit of INR1,467m; Firstcall recommends 'Buy'
IndiaNotes.com
 
Firstcall irb infrastructure_developers_ltd_15_june15
Firstcall irb infrastructure_developers_ltd_15_june15Firstcall irb infrastructure_developers_ltd_15_june15
Firstcall irb infrastructure_developers_ltd_15_june15IndiaNotes.com
 
AIA Engineering Q4FY15: Firstcall recommend for target of 1125
AIA Engineering Q4FY15: Firstcall recommend for target of 1125AIA Engineering Q4FY15: Firstcall recommend for target of 1125
AIA Engineering Q4FY15: Firstcall recommend for target of 1125
IndiaNotes.com
 
ATS Company Reports: Camlin fine sciences
ATS Company Reports: Camlin fine sciencesATS Company Reports: Camlin fine sciences
ATS Company Reports: Camlin fine sciences
Aditya Trading Solutions Pvt Ltd
 
Cipla Q2 disappoints, gearing up for strong H2FY15E
Cipla Q2 disappoints, gearing up for strong H2FY15ECipla Q2 disappoints, gearing up for strong H2FY15E
Cipla Q2 disappoints, gearing up for strong H2FY15E
IndiaNotes.com
 
Nirmal pi industries_03_aug15
Nirmal pi industries_03_aug15Nirmal pi industries_03_aug15
Nirmal pi industries_03_aug15
IndiaNotes.com
 

Similar to Atul Auto: Aims at Rs1000 cr turnover in the medium term (20)

Lumax Industries quarterly results above estimates; buy
Lumax Industries quarterly results above estimates; buyLumax Industries quarterly results above estimates; buy
Lumax Industries quarterly results above estimates; buy
 
Ashok Leyland Q1FY15: Losses narrowed down to Rs48 mn, hold
 Ashok Leyland Q1FY15: Losses narrowed down to Rs48 mn, hold Ashok Leyland Q1FY15: Losses narrowed down to Rs48 mn, hold
Ashok Leyland Q1FY15: Losses narrowed down to Rs48 mn, hold
 
Mahindra &Mahindra Q1FY15 profits better than estimates - Hold - SPA Securities
Mahindra &Mahindra Q1FY15 profits better than estimates - Hold - SPA SecuritiesMahindra &Mahindra Q1FY15 profits better than estimates - Hold - SPA Securities
Mahindra &Mahindra Q1FY15 profits better than estimates - Hold - SPA Securities
 
ATS Company Reports: Nrb bearing
ATS Company Reports: Nrb bearingATS Company Reports: Nrb bearing
ATS Company Reports: Nrb bearing
 
Gabriel India: Q4FY15 net profit up 55.52% y/y to INR129.55m; 'Buy'
Gabriel India: Q4FY15 net profit up 55.52% y/y to INR129.55m; 'Buy'Gabriel India: Q4FY15 net profit up 55.52% y/y to INR129.55m; 'Buy'
Gabriel India: Q4FY15 net profit up 55.52% y/y to INR129.55m; 'Buy'
 
Skipper remains leading player in the transmission tower business
Skipper remains leading player in the transmission tower businessSkipper remains leading player in the transmission tower business
Skipper remains leading player in the transmission tower business
 
Setco Automotive Q1FY15: Revenue in-line; PAT below estimates - SPA Securities
Setco Automotive Q1FY15: Revenue in-line; PAT below estimates - SPA SecuritiesSetco Automotive Q1FY15: Revenue in-line; PAT below estimates - SPA Securities
Setco Automotive Q1FY15: Revenue in-line; PAT below estimates - SPA Securities
 
Cyient announces acquisition of GSE-Asia, maintain hold
Cyient announces acquisition of GSE-Asia, maintain holdCyient announces acquisition of GSE-Asia, maintain hold
Cyient announces acquisition of GSE-Asia, maintain hold
 
Voltas Q4FY15: Firstcall recommend 'Buy'
Voltas Q4FY15: Firstcall recommend 'Buy'Voltas Q4FY15: Firstcall recommend 'Buy'
Voltas Q4FY15: Firstcall recommend 'Buy'
 
ATS Company Reports: Elgi equipments ltd.
ATS Company Reports: Elgi equipments ltd.ATS Company Reports: Elgi equipments ltd.
ATS Company Reports: Elgi equipments ltd.
 
Patel Integrated Logistics: FY15 net profit up 155%; transportation sector re...
Patel Integrated Logistics: FY15 net profit up 155%; transportation sector re...Patel Integrated Logistics: FY15 net profit up 155%; transportation sector re...
Patel Integrated Logistics: FY15 net profit up 155%; transportation sector re...
 
ENIL 1QFY18
ENIL 1QFY18ENIL 1QFY18
ENIL 1QFY18
 
Medium to Long Term Investment Idea: Capital Trust
Medium to Long Term Investment Idea: Capital TrustMedium to Long Term Investment Idea: Capital Trust
Medium to Long Term Investment Idea: Capital Trust
 
Castrol India clocks Q1CY15 net profit of INR1,467m; Firstcall recommends 'Buy'
Castrol India clocks Q1CY15 net profit of INR1,467m; Firstcall recommends 'Buy'Castrol India clocks Q1CY15 net profit of INR1,467m; Firstcall recommends 'Buy'
Castrol India clocks Q1CY15 net profit of INR1,467m; Firstcall recommends 'Buy'
 
Firstcall irb infrastructure_developers_ltd_15_june15
Firstcall irb infrastructure_developers_ltd_15_june15Firstcall irb infrastructure_developers_ltd_15_june15
Firstcall irb infrastructure_developers_ltd_15_june15
 
AIA Engineering Q4FY15: Firstcall recommend for target of 1125
AIA Engineering Q4FY15: Firstcall recommend for target of 1125AIA Engineering Q4FY15: Firstcall recommend for target of 1125
AIA Engineering Q4FY15: Firstcall recommend for target of 1125
 
ATS Company Reports: Camlin fine sciences
ATS Company Reports: Camlin fine sciencesATS Company Reports: Camlin fine sciences
ATS Company Reports: Camlin fine sciences
 
Cipla Q2 disappoints, gearing up for strong H2FY15E
Cipla Q2 disappoints, gearing up for strong H2FY15ECipla Q2 disappoints, gearing up for strong H2FY15E
Cipla Q2 disappoints, gearing up for strong H2FY15E
 
Nirmal pi industries_03_aug15
Nirmal pi industries_03_aug15Nirmal pi industries_03_aug15
Nirmal pi industries_03_aug15
 
Daily equity report
Daily equity reportDaily equity report
Daily equity report
 

More from IndiaNotes.com

Fce glaxo smithkline_12aug15
Fce glaxo smithkline_12aug15Fce glaxo smithkline_12aug15
Fce glaxo smithkline_12aug15IndiaNotes.com
 
GSK Consumer: Horlicks strengthens its position as No.1 brand across India
GSK Consumer: Horlicks strengthens its position as No.1 brand across IndiaGSK Consumer: Horlicks strengthens its position as No.1 brand across India
GSK Consumer: Horlicks strengthens its position as No.1 brand across India
IndiaNotes.com
 
Buy Makers Laboratories, company growing rapidly with strong thrust on brande...
Buy Makers Laboratories, company growing rapidly with strong thrust on brande...Buy Makers Laboratories, company growing rapidly with strong thrust on brande...
Buy Makers Laboratories, company growing rapidly with strong thrust on brande...
IndiaNotes.com
 
Buy Multibase India, globalisation of the auto component sector to benefit th...
Buy Multibase India, globalisation of the auto component sector to benefit th...Buy Multibase India, globalisation of the auto component sector to benefit th...
Buy Multibase India, globalisation of the auto component sector to benefit th...
IndiaNotes.com
 
Capital First: Long-term credit rating is rated highly at AA+ by CARE
Capital First: Long-term credit rating is rated highly at AA+ by CARECapital First: Long-term credit rating is rated highly at AA+ by CARE
Capital First: Long-term credit rating is rated highly at AA+ by CARE
IndiaNotes.com
 
Orient Cement: Best placed to benefit from demand revival in AP & Telengana r...
Orient Cement: Best placed to benefit from demand revival in AP & Telengana r...Orient Cement: Best placed to benefit from demand revival in AP & Telengana r...
Orient Cement: Best placed to benefit from demand revival in AP & Telengana r...
IndiaNotes.com
 
Canara Bank's operating performance to improve in remaining 9MFY16E
Canara Bank's operating performance to improve in remaining 9MFY16ECanara Bank's operating performance to improve in remaining 9MFY16E
Canara Bank's operating performance to improve in remaining 9MFY16E
IndiaNotes.com
 
Nirmal lupin 06_aug15
Nirmal lupin 06_aug15Nirmal lupin 06_aug15
Nirmal lupin 06_aug15
IndiaNotes.com
 
Buy Jenburkt Pharmaceuticals; government's amended FDI policy to cover medica...
Buy Jenburkt Pharmaceuticals; government's amended FDI policy to cover medica...Buy Jenburkt Pharmaceuticals; government's amended FDI policy to cover medica...
Buy Jenburkt Pharmaceuticals; government's amended FDI policy to cover medica...
IndiaNotes.com
 
Hexaware Technologies adds 9 clients in Q2CY15, Buy
Hexaware Technologies adds 9 clients in Q2CY15, BuyHexaware Technologies adds 9 clients in Q2CY15, Buy
Hexaware Technologies adds 9 clients in Q2CY15, Buy
IndiaNotes.com
 
Indoco Remedies: Weak domestic growth offsets export revenues in Q1FY16; Hold
Indoco Remedies: Weak domestic growth offsets export revenues in Q1FY16; HoldIndoco Remedies: Weak domestic growth offsets export revenues in Q1FY16; Hold
Indoco Remedies: Weak domestic growth offsets export revenues in Q1FY16; Hold
IndiaNotes.com
 
Fce thermax 31_jul15
Fce thermax 31_jul15Fce thermax 31_jul15
Fce thermax 31_jul15
IndiaNotes.com
 
PI Industries: Custom synthesis exports deliver growth of ~26% in Q1FY16; Buy
PI Industries: Custom synthesis exports deliver growth of ~26% in Q1FY16; BuyPI Industries: Custom synthesis exports deliver growth of ~26% in Q1FY16; Buy
PI Industries: Custom synthesis exports deliver growth of ~26% in Q1FY16; Buy
IndiaNotes.com
 
Torrent Pharma Q1FY16: IndiaNivesh maintain 'buy' for an upgraded price target
Torrent Pharma Q1FY16: IndiaNivesh maintain 'buy' for an upgraded price targetTorrent Pharma Q1FY16: IndiaNivesh maintain 'buy' for an upgraded price target
Torrent Pharma Q1FY16: IndiaNivesh maintain 'buy' for an upgraded price target
IndiaNotes.com
 
IndiaNivesh maintain 'buy' on this textile scrip with upgraded target after Q...
IndiaNivesh maintain 'buy' on this textile scrip with upgraded target after Q...IndiaNivesh maintain 'buy' on this textile scrip with upgraded target after Q...
IndiaNivesh maintain 'buy' on this textile scrip with upgraded target after Q...
IndiaNotes.com
 
Agro Tech Foods: Demonstrates continued strong growth in tough environment; Buy
Agro Tech Foods: Demonstrates continued strong growth in tough environment; BuyAgro Tech Foods: Demonstrates continued strong growth in tough environment; Buy
Agro Tech Foods: Demonstrates continued strong growth in tough environment; Buy
IndiaNotes.com
 
ATS Research positive on Deepak Nitrate, buy at CMP and further add on declines
ATS Research positive on Deepak Nitrate, buy at CMP and further add on declinesATS Research positive on Deepak Nitrate, buy at CMP and further add on declines
ATS Research positive on Deepak Nitrate, buy at CMP and further add on declines
IndiaNotes.com
 
Firstcall can fin_homes_ltd_29_july15
Firstcall can fin_homes_ltd_29_july15Firstcall can fin_homes_ltd_29_july15
Firstcall can fin_homes_ltd_29_july15IndiaNotes.com
 
Fce sqs india_29_jul15
Fce sqs india_29_jul15Fce sqs india_29_jul15
Fce sqs india_29_jul15IndiaNotes.com
 
Nb maxwell 29_july15
Nb  maxwell 29_july15Nb  maxwell 29_july15
Nb maxwell 29_july15
IndiaNotes.com
 

More from IndiaNotes.com (20)

Fce glaxo smithkline_12aug15
Fce glaxo smithkline_12aug15Fce glaxo smithkline_12aug15
Fce glaxo smithkline_12aug15
 
GSK Consumer: Horlicks strengthens its position as No.1 brand across India
GSK Consumer: Horlicks strengthens its position as No.1 brand across IndiaGSK Consumer: Horlicks strengthens its position as No.1 brand across India
GSK Consumer: Horlicks strengthens its position as No.1 brand across India
 
Buy Makers Laboratories, company growing rapidly with strong thrust on brande...
Buy Makers Laboratories, company growing rapidly with strong thrust on brande...Buy Makers Laboratories, company growing rapidly with strong thrust on brande...
Buy Makers Laboratories, company growing rapidly with strong thrust on brande...
 
Buy Multibase India, globalisation of the auto component sector to benefit th...
Buy Multibase India, globalisation of the auto component sector to benefit th...Buy Multibase India, globalisation of the auto component sector to benefit th...
Buy Multibase India, globalisation of the auto component sector to benefit th...
 
Capital First: Long-term credit rating is rated highly at AA+ by CARE
Capital First: Long-term credit rating is rated highly at AA+ by CARECapital First: Long-term credit rating is rated highly at AA+ by CARE
Capital First: Long-term credit rating is rated highly at AA+ by CARE
 
Orient Cement: Best placed to benefit from demand revival in AP & Telengana r...
Orient Cement: Best placed to benefit from demand revival in AP & Telengana r...Orient Cement: Best placed to benefit from demand revival in AP & Telengana r...
Orient Cement: Best placed to benefit from demand revival in AP & Telengana r...
 
Canara Bank's operating performance to improve in remaining 9MFY16E
Canara Bank's operating performance to improve in remaining 9MFY16ECanara Bank's operating performance to improve in remaining 9MFY16E
Canara Bank's operating performance to improve in remaining 9MFY16E
 
Nirmal lupin 06_aug15
Nirmal lupin 06_aug15Nirmal lupin 06_aug15
Nirmal lupin 06_aug15
 
Buy Jenburkt Pharmaceuticals; government's amended FDI policy to cover medica...
Buy Jenburkt Pharmaceuticals; government's amended FDI policy to cover medica...Buy Jenburkt Pharmaceuticals; government's amended FDI policy to cover medica...
Buy Jenburkt Pharmaceuticals; government's amended FDI policy to cover medica...
 
Hexaware Technologies adds 9 clients in Q2CY15, Buy
Hexaware Technologies adds 9 clients in Q2CY15, BuyHexaware Technologies adds 9 clients in Q2CY15, Buy
Hexaware Technologies adds 9 clients in Q2CY15, Buy
 
Indoco Remedies: Weak domestic growth offsets export revenues in Q1FY16; Hold
Indoco Remedies: Weak domestic growth offsets export revenues in Q1FY16; HoldIndoco Remedies: Weak domestic growth offsets export revenues in Q1FY16; Hold
Indoco Remedies: Weak domestic growth offsets export revenues in Q1FY16; Hold
 
Fce thermax 31_jul15
Fce thermax 31_jul15Fce thermax 31_jul15
Fce thermax 31_jul15
 
PI Industries: Custom synthesis exports deliver growth of ~26% in Q1FY16; Buy
PI Industries: Custom synthesis exports deliver growth of ~26% in Q1FY16; BuyPI Industries: Custom synthesis exports deliver growth of ~26% in Q1FY16; Buy
PI Industries: Custom synthesis exports deliver growth of ~26% in Q1FY16; Buy
 
Torrent Pharma Q1FY16: IndiaNivesh maintain 'buy' for an upgraded price target
Torrent Pharma Q1FY16: IndiaNivesh maintain 'buy' for an upgraded price targetTorrent Pharma Q1FY16: IndiaNivesh maintain 'buy' for an upgraded price target
Torrent Pharma Q1FY16: IndiaNivesh maintain 'buy' for an upgraded price target
 
IndiaNivesh maintain 'buy' on this textile scrip with upgraded target after Q...
IndiaNivesh maintain 'buy' on this textile scrip with upgraded target after Q...IndiaNivesh maintain 'buy' on this textile scrip with upgraded target after Q...
IndiaNivesh maintain 'buy' on this textile scrip with upgraded target after Q...
 
Agro Tech Foods: Demonstrates continued strong growth in tough environment; Buy
Agro Tech Foods: Demonstrates continued strong growth in tough environment; BuyAgro Tech Foods: Demonstrates continued strong growth in tough environment; Buy
Agro Tech Foods: Demonstrates continued strong growth in tough environment; Buy
 
ATS Research positive on Deepak Nitrate, buy at CMP and further add on declines
ATS Research positive on Deepak Nitrate, buy at CMP and further add on declinesATS Research positive on Deepak Nitrate, buy at CMP and further add on declines
ATS Research positive on Deepak Nitrate, buy at CMP and further add on declines
 
Firstcall can fin_homes_ltd_29_july15
Firstcall can fin_homes_ltd_29_july15Firstcall can fin_homes_ltd_29_july15
Firstcall can fin_homes_ltd_29_july15
 
Fce sqs india_29_jul15
Fce sqs india_29_jul15Fce sqs india_29_jul15
Fce sqs india_29_jul15
 
Nb maxwell 29_july15
Nb  maxwell 29_july15Nb  maxwell 29_july15
Nb maxwell 29_july15
 

Recently uploaded

BONKMILLON Unleashes Its Bonkers Potential on Solana.pdf
BONKMILLON Unleashes Its Bonkers Potential on Solana.pdfBONKMILLON Unleashes Its Bonkers Potential on Solana.pdf
BONKMILLON Unleashes Its Bonkers Potential on Solana.pdf
coingabbar
 
5 Tips for Creating Standard Financial Reports
5 Tips for Creating Standard Financial Reports5 Tips for Creating Standard Financial Reports
5 Tips for Creating Standard Financial Reports
EasyReports
 
一比一原版(GWU,GW毕业证)加利福尼亚大学|尔湾分校毕业证如何办理
一比一原版(GWU,GW毕业证)加利福尼亚大学|尔湾分校毕业证如何办理一比一原版(GWU,GW毕业证)加利福尼亚大学|尔湾分校毕业证如何办理
一比一原版(GWU,GW毕业证)加利福尼亚大学|尔湾分校毕业证如何办理
obyzuk
 
SWAIAP Fraud Risk Mitigation Prof Oyedokun.pptx
SWAIAP Fraud Risk Mitigation   Prof Oyedokun.pptxSWAIAP Fraud Risk Mitigation   Prof Oyedokun.pptx
SWAIAP Fraud Risk Mitigation Prof Oyedokun.pptx
Godwin Emmanuel Oyedokun MBA MSc PhD FCA FCTI FCNA CFE FFAR
 
Which Crypto to Buy Today for Short-Term in May-June 2024.pdf
Which Crypto to Buy Today for Short-Term in May-June 2024.pdfWhich Crypto to Buy Today for Short-Term in May-June 2024.pdf
Which Crypto to Buy Today for Short-Term in May-June 2024.pdf
Kezex (KZX)
 
Globalization (Nike) Presentation PPT Poster Infographic.pdf
Globalization (Nike) Presentation PPT Poster Infographic.pdfGlobalization (Nike) Presentation PPT Poster Infographic.pdf
Globalization (Nike) Presentation PPT Poster Infographic.pdf
VohnArchieEdjan
 
Managing marketing information to gain customer insights
Managing marketing information to gain customer insightsManaging marketing information to gain customer insights
Managing marketing information to gain customer insights
sanamalam3
 
How Non-Banking Financial Companies Empower Startups With Venture Debt Financing
How Non-Banking Financial Companies Empower Startups With Venture Debt FinancingHow Non-Banking Financial Companies Empower Startups With Venture Debt Financing
How Non-Banking Financial Companies Empower Startups With Venture Debt Financing
Vighnesh Shashtri
 
一比一原版(IC毕业证)帝国理工大学毕业证如何办理
一比一原版(IC毕业证)帝国理工大学毕业证如何办理一比一原版(IC毕业证)帝国理工大学毕业证如何办理
一比一原版(IC毕业证)帝国理工大学毕业证如何办理
conose1
 
Earn a passive income with prosocial investing
Earn a passive income with prosocial investingEarn a passive income with prosocial investing
Earn a passive income with prosocial investing
Colin R. Turner
 
一比一原版(UoB毕业证)伯明翰大学毕业证如何办理
一比一原版(UoB毕业证)伯明翰大学毕业证如何办理一比一原版(UoB毕业证)伯明翰大学毕业证如何办理
一比一原版(UoB毕业证)伯明翰大学毕业证如何办理
nexop1
 
where can I find a legit pi merchant online
where can I find a legit pi merchant onlinewhere can I find a legit pi merchant online
where can I find a legit pi merchant online
DOT TECH
 
What price will pi network be listed on exchanges
What price will pi network be listed on exchangesWhat price will pi network be listed on exchanges
What price will pi network be listed on exchanges
DOT TECH
 
An Overview of the Prosocial dHEDGE Vault works
An Overview of the Prosocial dHEDGE Vault worksAn Overview of the Prosocial dHEDGE Vault works
An Overview of the Prosocial dHEDGE Vault works
Colin R. Turner
 
Instant Issue Debit Cards
Instant Issue Debit CardsInstant Issue Debit Cards
Instant Issue Debit Cards
egoetzinger
 
Donald Trump Presentation and his life.pptx
Donald Trump Presentation and his life.pptxDonald Trump Presentation and his life.pptx
Donald Trump Presentation and his life.pptx
SerdarHudaykuliyew
 
The secret way to sell pi coins effortlessly.
The secret way to sell pi coins effortlessly.The secret way to sell pi coins effortlessly.
The secret way to sell pi coins effortlessly.
DOT TECH
 
Tumelo-deep-dive-into-pass-through-voting-Feb23 (1).pdf
Tumelo-deep-dive-into-pass-through-voting-Feb23 (1).pdfTumelo-deep-dive-into-pass-through-voting-Feb23 (1).pdf
Tumelo-deep-dive-into-pass-through-voting-Feb23 (1).pdf
Henry Tapper
 
Turin Startup Ecosystem 2024 - Ricerca sulle Startup e il Sistema dell'Innov...
Turin Startup Ecosystem 2024  - Ricerca sulle Startup e il Sistema dell'Innov...Turin Startup Ecosystem 2024  - Ricerca sulle Startup e il Sistema dell'Innov...
Turin Startup Ecosystem 2024 - Ricerca sulle Startup e il Sistema dell'Innov...
Quotidiano Piemontese
 
2. Elemental Economics - Mineral demand.pdf
2. Elemental Economics - Mineral demand.pdf2. Elemental Economics - Mineral demand.pdf
2. Elemental Economics - Mineral demand.pdf
Neal Brewster
 

Recently uploaded (20)

BONKMILLON Unleashes Its Bonkers Potential on Solana.pdf
BONKMILLON Unleashes Its Bonkers Potential on Solana.pdfBONKMILLON Unleashes Its Bonkers Potential on Solana.pdf
BONKMILLON Unleashes Its Bonkers Potential on Solana.pdf
 
5 Tips for Creating Standard Financial Reports
5 Tips for Creating Standard Financial Reports5 Tips for Creating Standard Financial Reports
5 Tips for Creating Standard Financial Reports
 
一比一原版(GWU,GW毕业证)加利福尼亚大学|尔湾分校毕业证如何办理
一比一原版(GWU,GW毕业证)加利福尼亚大学|尔湾分校毕业证如何办理一比一原版(GWU,GW毕业证)加利福尼亚大学|尔湾分校毕业证如何办理
一比一原版(GWU,GW毕业证)加利福尼亚大学|尔湾分校毕业证如何办理
 
SWAIAP Fraud Risk Mitigation Prof Oyedokun.pptx
SWAIAP Fraud Risk Mitigation   Prof Oyedokun.pptxSWAIAP Fraud Risk Mitigation   Prof Oyedokun.pptx
SWAIAP Fraud Risk Mitigation Prof Oyedokun.pptx
 
Which Crypto to Buy Today for Short-Term in May-June 2024.pdf
Which Crypto to Buy Today for Short-Term in May-June 2024.pdfWhich Crypto to Buy Today for Short-Term in May-June 2024.pdf
Which Crypto to Buy Today for Short-Term in May-June 2024.pdf
 
Globalization (Nike) Presentation PPT Poster Infographic.pdf
Globalization (Nike) Presentation PPT Poster Infographic.pdfGlobalization (Nike) Presentation PPT Poster Infographic.pdf
Globalization (Nike) Presentation PPT Poster Infographic.pdf
 
Managing marketing information to gain customer insights
Managing marketing information to gain customer insightsManaging marketing information to gain customer insights
Managing marketing information to gain customer insights
 
How Non-Banking Financial Companies Empower Startups With Venture Debt Financing
How Non-Banking Financial Companies Empower Startups With Venture Debt FinancingHow Non-Banking Financial Companies Empower Startups With Venture Debt Financing
How Non-Banking Financial Companies Empower Startups With Venture Debt Financing
 
一比一原版(IC毕业证)帝国理工大学毕业证如何办理
一比一原版(IC毕业证)帝国理工大学毕业证如何办理一比一原版(IC毕业证)帝国理工大学毕业证如何办理
一比一原版(IC毕业证)帝国理工大学毕业证如何办理
 
Earn a passive income with prosocial investing
Earn a passive income with prosocial investingEarn a passive income with prosocial investing
Earn a passive income with prosocial investing
 
一比一原版(UoB毕业证)伯明翰大学毕业证如何办理
一比一原版(UoB毕业证)伯明翰大学毕业证如何办理一比一原版(UoB毕业证)伯明翰大学毕业证如何办理
一比一原版(UoB毕业证)伯明翰大学毕业证如何办理
 
where can I find a legit pi merchant online
where can I find a legit pi merchant onlinewhere can I find a legit pi merchant online
where can I find a legit pi merchant online
 
What price will pi network be listed on exchanges
What price will pi network be listed on exchangesWhat price will pi network be listed on exchanges
What price will pi network be listed on exchanges
 
An Overview of the Prosocial dHEDGE Vault works
An Overview of the Prosocial dHEDGE Vault worksAn Overview of the Prosocial dHEDGE Vault works
An Overview of the Prosocial dHEDGE Vault works
 
Instant Issue Debit Cards
Instant Issue Debit CardsInstant Issue Debit Cards
Instant Issue Debit Cards
 
Donald Trump Presentation and his life.pptx
Donald Trump Presentation and his life.pptxDonald Trump Presentation and his life.pptx
Donald Trump Presentation and his life.pptx
 
The secret way to sell pi coins effortlessly.
The secret way to sell pi coins effortlessly.The secret way to sell pi coins effortlessly.
The secret way to sell pi coins effortlessly.
 
Tumelo-deep-dive-into-pass-through-voting-Feb23 (1).pdf
Tumelo-deep-dive-into-pass-through-voting-Feb23 (1).pdfTumelo-deep-dive-into-pass-through-voting-Feb23 (1).pdf
Tumelo-deep-dive-into-pass-through-voting-Feb23 (1).pdf
 
Turin Startup Ecosystem 2024 - Ricerca sulle Startup e il Sistema dell'Innov...
Turin Startup Ecosystem 2024  - Ricerca sulle Startup e il Sistema dell'Innov...Turin Startup Ecosystem 2024  - Ricerca sulle Startup e il Sistema dell'Innov...
Turin Startup Ecosystem 2024 - Ricerca sulle Startup e il Sistema dell'Innov...
 
2. Elemental Economics - Mineral demand.pdf
2. Elemental Economics - Mineral demand.pdf2. Elemental Economics - Mineral demand.pdf
2. Elemental Economics - Mineral demand.pdf
 

Atul Auto: Aims at Rs1000 cr turnover in the medium term

  • 1. 1 Automobiles (3 wheelers) Atul Auto Sensex: 28420 CMP: INR 480 Expandingcapacityby1.5x Atul Auto has current capacity of 48000 units. The company plans to expand capacity by 1.5x to 120000 units in the next 2 years. While capacity of 12000 units will be created by removing some bottlenecks at the existing unit at an investment of INR 30-50 mn, another 60000 units expansion will take place at a greenfield plant in Ahmedabad. Total investment for the new plant would be ~INR 1.50 bn of which INR 0.40 bn has already been invested. The company plans to undertake the commercial production of the new plant in or before FY18. Atul's current capacity is miniscule compared to the established players in the industry and their capacity enhancement plans will help them in achieving scale. Product Portfolio Currently Atul Auto's product portfolio comprises of 45 variants under 4 brands i.e. Shakti, Smart, Gem and Gemini. The company plans to launch its new 0.35 ton petrol 3 wheeler in H2FY16. Petrol 3 wheelers account for 46% of passenger 3 wheeler market in India and almost 100% of passenger 3 wheeler exports from India. The company enjoys a market share of ~7.5% in India despite being present in only ~56% of the market. With the launch of this new vehicle, we expect Atul Auto to further expand its market share in India. Aggressive Export plans Exports account for 43% of total Indian 3 wheeler industry sales whereas it accounts for 3.5% of Atul Auto's sales. Almost entire July 21, 2015 VISITNOTE export market of 408000 units of 3 wheelers is 0.35 ton petrol. While previously Atul was not present in the segment, now with its 0.35 ton 3 wheeler, we expect the company to clock significant growth in export volumes with its widening target audience. The company too plans to scale up export volumes to more than 10000 units over the next 3-5 years. Industry Outlook The management expects 3 wheeler industry to grow at a CAGR of 6%-8% in the medium term. Both passenger and goods 3 wheelers are expected to grow on the back of demand from both urban and rural areas. Atul Auto also expects limited competition & impact from electric 3 wheelers (or E-rickshaws) and RE60 of Bajaj Auto as these vehicles are likely to find buyers only in urban areas and feeder routes. The company anyways till now does not have significant presence in urban markets. Outlook & Valuation Atul Auto, being a relatively small player in the 3 wheeler industry, is expected to grow on the back of widening product portfolio, growing distribution reach and expanding market opportunity size. Increase in capacity by 1.5x will help the company in achieving scale, enhance market share and fulfill the near term vision of the management of achieving sales of 100000 3-wheelers. Topline and bottomline grew at a CAGR of 16.4% and 23.4% between FY13-15. At CMP the stock is trading at a PE of 25.8x FY15 earnings. Shareholding (%) Mar-15 Promoters 52.70 FIIs 11.45 DIIs 8.27 Others 27.58 Relative Price Performance Key Data BSE Code 531795 NSE Code ATULAUTO Bloomberg Code ATA IN Reuters Code ATUL.BO Shares Outstanding (mn) 21.94 Face Value 5 Mcap (INR bn) 10.25 52 Week H/L 722.00/264.13 2W Avg. Qty.NSE 72189 Free Float (INR Bn) 4.85 Beta 1.24 (INR mn) FY12 FY13 FY14 FY15 Net Sales 2988 3638 4301 4928 Growth (%) 47.90% 21.76% 18.22% 14.57% EBIDTAM (%) 8.86% 11.01% 10.55% 11.75% Adj. PAT 155 259 296 394 Growth (%) 64.28% 66.89% 14.45% 33.13% Adj. EPS (INR) 20.54 23.11 26.45 17.61 P/E(x) 5.41 6.27 13.32 30.91 EV/EBIDTA 2.89 3.10 7.70 20.58 Net Debt/Equity 0.07 0.00 0.00 0.00 RoACE (%) 28.02% 36.96% 33.21% 33.25% RoAE (%) 32.17% 39.71% 35.11% 36.60% We met the management of Atul Auto and visited their manufacturing facilities to understand the dynamics of the 3 wheeler industry & steps they are taking to further strengthen their market share. The company plans to launch 0.35 ton petrol 3 wheeler this year which will complete its product portfolio and expand its addressable market size. Atul Auto's medium term strategy is to achieve 100000 unit sales and INR 1000 crs turnover. Given below are the key takeaways from the visit:- Prashant Biyani prashant.biyani@spagroupindia.com Ph. No. 91 33 4011 4800 (Ext. 833) 40 60 80 100 120 140 160 Jul-14 Aug-14 Sep-14 Oct-14 Nov-14 Dec-14 Jan-15 Feb-15 Mar-15 Apr-15 May-15 Jun-15 Jul-15 Atul Auto Sensex
  • 2. 2 Automobiles (3 wheelers) Financials Income Statement Year End March (INR mn) FY12 FY13 FY14 FY15 Net Sales 2988 3638 4301 4928 Growth in Sales (%) 47.90% 21.76% 18.22% 14.57% Cost of goods sold 2376 2843 3317 3722 Employees Cost 156 197 257 324 Other Expenses 174 181 247 303 Total Expenditure 2724 3238 3847 4349 EBIDTA (without OI) 265 401 454 579 % Growth -36.23% -51.38% -13.28% -27.58% EBITDA Margin % 8.86% 11.01% 10.55% 11.75% Depreciation/Amortization 43 44 52 56 EBIT 222 356 402 523 EBIT Margin % 7.43% 9.79% 9.34% 10.62% Interest Expense 8 4 4 6 Other Income 18 20 30 75 Exceptionals 1 0 2 11 EBT 232 372 428 593 Tax Expenses 77 113 130 187 APAT 155 259 296 394 % Growth 64.28% 66.89% 14.45% 33.13% APAT Margin % 5.19% 7.11% 6.89% 8.00% Balance Sheet Year End March (INR mn) FY12 FY13 FY14 FY15 Sources of funds Share capital 76 112 112 112 Reserves & Surplus 485 631 833 1099 Total Networth 561 743 945 1211 Total Debt 39 0 0 0 Total Liabilities 600 743 945 1211 Application of funds Net Block 400 431 527 799 Capital Work-in-Progress 16 50 6 0 Investments 12 12 12 10 Total Current Assets 493 699 851 892 Total Current Liabilities 299 440 438 507 Net Current Assets 194 258 413 385 Net Deferred Tax (47) (45) (61) (52) Other Assets 25 37 47 68 Total Assets 600 743 945 1211 Cash Flow Year End March (INR mn) FY12 FY13 FY14 FY15 EBT 232 372 428 593 Less: Other Income/Exceptionals (18) (20) (30) (75) Add:Depreciation 43 44 52 56 Add: Interest paid 8 4 4 6 Direct taxes paid (70) (122) (134) 0 Change in Working Capital (26) 202 (84) (150) Cash Flow from operations (a) 169 481 236 429 Change in Fixed Assets 20 (75) (148) (327) Change in CWIP (16) (34) 44 6 Change in Investments 11 0 0 12 Others (38) (12) (11) (21) Cash Flow from Investing (b) (23) (121) (115) (329) Change in Equity 15 37 0 0 Debt Raised/(Repaid) (21) (39) 0 0 Dividend paid (27) (43) (77) (96) Interest paid (8) (4) (4) (6) Others (20) (44) 30 (176) Cash Flow from Financing (c ) (61) (93) (50) (278) Net Change in Cash (a+b+c) 85 267 71 (178) Opening Cash 28 114 381 452 Closing Cash 114 381 451 274 Key Ratios Year End March FY12 FY13 FY14 FY15 Per Share Data (INR) Adj. EPS 20.54 23.11 26.45 17.61 Growth (%) 32.29% 12.50% 14.45% -33.44% CEPS 35.43 54.35 62.43 80.68 DPS 4.85 5.88 7.35 5.00 BVPS 74.29 66.34 84.34 54.05 Return Ratios (%) RoACE 28.02% 36.96% 33.21% 33.25% RoANW 32.17% 39.71% 35.11% 36.60% Liquidity Ratios Net Debt/Equity 0.07 0.00 0.00 0.00 Current Ratio 1.65 1.59 1.94 1.76 Efficiency Ratios Asset Turnover Ratio 5.62 5.42 5.10 4.57 Inventory Days 38 34 25 24 Debtor Days 7 7 9 17 Creditor days 18 24 28 28 Valuation Ratios P/E(x) 5.41 6.27 13.32 30.91 P/BV (x) 1.50 2.19 4.18 10.07 P/CEPS (x) 3.14 2.67 5.64 6.74 Dividend Yield (%) 4.36% 4.05% 2.09% 0.92% EV/Net Sales (x) 0.26 0.34 0.81 2.42 EV/EBIDTA(x) 2.89 3.10 7.70 20.58
  • 3. 3 Automobiles (3 wheelers) For More Information Visit Us At : www.spasecurities.com Sharad Avasthi Head - Equity Research sharad.avasthi@spagroupindia.com Tel.: +91-33-4011 4800 Ext.832 SPA Securities Ltd: Mittal Court, A-Wing, 10th Floor, Nariman Point, Mumbai - 400 021, Tel. No. : +91-022-4289 5600, Fax: +91 (22) 2657 3708/9 Analyst Certification of Independence: The analyst(s) for this report certifies that all the views expressed in this report accurately reflect his or her personal views about the subject company(ies) or issuers and no part of his or hercompensationwas,isorwillbe,directlyorindirectlyrelatedtospecificrecommendationsorviewsexpressedinthisreport.Theresearchanalystsareboundbystringentinternalregulationsandalsolegalandstatutoryrequirements of the Securities and Exchange Board of India (hereinafter "SEBI") and the analysts' compensation are completely delinked from all the other companies and/or entities of SPASecurities Limited, and have no bearing whatsoever on anyrecommendationthattheyhavegivenintheResearchReport. DisclaimerandDisclosuresasrequiredunderSEBI(Research Analyst)Regulations,2014:SPASecuritiesLimited(hereinafterreferasSPASecurities)anditsaffiliatesareengagedininvestmentbanking,investment advisory, stock broking, institutional equities, Mutual Fund Distributor and insurance broking. SPASecurities is a SEBI registered securities broking Company having membership of NSE, BSE & MCX for Equity, Future & Option, Currency Derivatives segment and Wholesale Debt Market. The Company is focused primarily on providing securities broking services to institutional clients and is empanelled as an approved securities broker with all the major Nationalised, PrivateandCo-operativebanks,Corporatehouses,InsuranceCompanies,FinancialInstitutions,AssetManagementCompaniesandProvidentFundTrusts.Detailsofaffiliatesareavailableonourwebsitei.e.www.spasecurities.com. Weherebydeclarethatouractivitieswereneithersuspendednorwehavedefaultedwithanystockexchangeauthoritywithwhom weareregisteredinthelastfiveyears.WehavenotbeendebarredfromdoingbusinessbyanyStock Exchange/SEBI or any other authorities, nor has our certificate of registration been cancelled by SEBI at any point of time. GeneralDisclosures: ThisResearchReport(hereinaftercalled"report")hasbeenpreparedbySPASecuritiesandismeantforsoleusebytherecipientandnotforcirculation.ThisReportdoesnotconstituteapersonalrecommendation or take into account the particular investment objectives, financial situations, or needs of individual clients. The recommendations, if any, made herein are expression of views and/or opinions and should not be deemed or construed tobeneitheradviceforthepurposeofpurchaseorsaleofanysecurity,(asdefinedundersection2(h)ofsecuritiesContracts(Regulation)Act.1956,throughSPASecuritiesnoranysolicitationorofferingofanyinvestment/tradingopportunity onbehalfoftheissuer(s)oftherespectivesecurity(ies)referredtoherein.RecipientsofthisReportshouldrelyoninformation/dataarisingoutoftheirowninvestigations.Readersareadvisedtoseekindependentprofessionaladvice and arrive at an informed trading/investment decision before executing any trades or making any investments. ThisReporthasbeenpreparedonthebasisofpubliclyavailableinformation,internallydevelopeddataandothersourcesbelievedbySPASecuritiestobereliable,althoughitsaccuracyandcompletenesscannotbeguaranteed.Such information has not been independently verified and no guaranty, representation of warranty, express or implied, is made as to its accuracy, completeness or correctness.Any review, retransmission or any other use is prohibited. The information, opinions, views expressed in this Research Report are those of the research analyst as at the date of this Research Report which are subject to change and do not represent to be an authority on the subject. While we would endeavour to update the information herein on a reasonable basis, we are under no obligation to update the information.Also, there may be regulatory, compliance or other reasons that prevent us from doing so. Hence all such information and opinions are subject to change without notice. Our salespeople, traders, and other professionals may provide oral or written market commentary or trading strategies to our clients that reflect opinions that are contrary to the opinions expressed herein, and our proprietary trading and investing businesses may make investment decisions that may be inconsistent with the recommendations expressed herein. This Research Report should be read and relied upon at the sole discretion and risk of the recipient. If you are dissatisfied with the contents of this complimentary Research Report or with the terms of this Disclaimer, your sole and exclusive remedy is to stop using this Research Report. Neither SPASecurities nor its affiliates or their respective directors, employees, agents or representatives shall be responsible or liable in any manner, directly or indirectly, for the losses or the damages sustained due to the investments made or any action taken on basis of this report, including but not restricted to, fluctuation in the prices of shares and bonds, changes in the currency rates, diminution in the NAVs, reduction in the dividend or income, etc. Compensation of our ResearchAnalysts is not based on any specific merchant banking, investment banking or brokerage service transactions. SPASecurities may have issued other reports in the past that are inconsistent with and reachdifferentconclusionfromtheinformationpresentedinthisreport. SPASecurities, its affiliates and employees may, from time to time, effect or have effected an own account transaction in, or deal as principal or agent in or for the securities mentioned in this document.They may perform or seek to perform investment banking or other services for, or solicit investment banking or other business from, any company referred to in this report. TheusershouldconsulttheirownadvisorstodeterminethemeritsandrisksofinvestmentandalsoreadtheRiskDisclosureDocumentsforCapitalMarketsandDerivativeSegmentsasprescribedbySecuritiesandExchangeBoard of India before investing in the Indian Markets. A graph of daily closing prices of securities is available at www.nseindia.com and http://economictimes.indiatimes.com/markets/stocks/stock-quotes. (Choose a company from the list on the browser and select the "three years" icon in the price chart). SPASecurities plans to register itself as a Research Entity under the SEBI (ResearchAnalysts) Regulations, 2014. Disclaimers in respect of jurisdiction: This report is not directed to, or intended for distribution to or use by, any person or entity who is a citizen or resident or located in any locality, state, country or other jurisdiction where such distribution, publication, reproduction, availability or use would be contrary to law or regulation or what would subject SPASecurities or its affiliates to any registration or licensing requirement within such jurisdiction. If this report is inadvertentlysendorhasreachedanyindividualinsuchcountry,especially,USA,thesamemaybeignoredandbroughttotheattentionofthesender.Thisdocumentmaynotbereproduced,distributedorpublishedforanypurposes without prior written approval of SPASecurities. List of Associates as per SEBI (Research Analyst) Regulations, 2014 • SPAInsurance Broking Services limited Statements on ownership and material conflicts of interest, compensation - SPA and Associates Disclosure of interest statement Yes/No SPA Securities/its Affiliates/Analyst/his or her Relative financial interest in the company No SPA Securities/its Affiliates/Analyst/his or her Relative actual/beneficial ownership of more than 1% in subject company at the end of the month Immediately preceding the date of the publication of the research report or date of public appearance. No Investment banking relationship with the company covered No Any other material conflict of interest at the time of publishing the research report No Receipt of compensation by SPA Securities or its Affiliated Companies from the subject company covered for in the last twelve months: • Managing/co-managing public offering of securities • Investmentbanking/merchantbanking/brokerageservices • products or services other than those above • in connection with research report No Whether Research Analyst has served as an officer, director or employee of the subject company covered No Whether the Research Analyst or Research Entity has been engaged in market making activity of the Subject Company; No For statements on ownership and material conflicts of interest, compensation, etc. for individual Research Analyst(s), please refer to each specific research report. SPA CAPITAL SERVICES LIMITED Investment Advisory Services, AMFI Reg. No. ARN-0007 SPA CAPITAL ADVISORS LIMITED SEBI registered Category-1 Merchant Bankers SEBI Regn. No. INM000010825 SPA COMTRADE PRIVATE LIMITED Member of NCDEX & MCX. NCDEX TMID-00729, NCDEXFMCNo.NCDEX/TCM/CORP/0714 SPAINSURANCE BROKING SERVICES LTD Direct Broker for Life and General Insurance Broking IRDA Lic. Code No. DB053/03 SPA Securities Ltd SEBI Reg. Nos. NSE Cash INB231178238 NSE Future & Option INF231173238 NSE Currency Derivatives INE231178238 BSE Cash INB011178234 BSE Currency Derivatives INE011178234 MCX-SX Cash INB261178231 MCX-SX Future & Option INF261178231 MCX-SX Currency Derivatives INE261178238 Mutual Fund ARN 77388 CDSLDP IN-DP-CDSL-485-2008 NSDLDP IN-DP-NSDL-316-2009